Industry and academia to share expertise in effort to develop improved methods to produce and characterize antibodies and reagents for neurological research
Industry and academia team up for the benefit of people suffering from ALS
A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide.
The partnership between The Montreal Neurological Institute and Hospital (MNI) and Takeda Pharmaceutical Company Limited (Takeda) will allow compounds developed by Takeda scientists to be tested on cell lines produced at the MNI.
Research symposium, public education event and ALS walk planned
Multiple events planned for this week will help educate the public about amyotrophic lateral sclerosis (ALS), a devastating disease that still has no cure.
The Tenaquip Foundation donation will allow for faster drug development, better care for ALS patients
A generous donation by The Tenaquip Foundation will improve the quality of care available to ALS patients at The Neuro, and increase the rate at which researchers can evaluate new ALS drugs.
ALS takes away the patient’s motor functions one at a time, and the progress of finding effective drugs to counter its insidious effects has been slow. June is ALS Month, a good time to update the public on the latest developments in ALS research taking place at The Neuro.
The Montreal Neurological Institute and Hospital (The Neuro) is recognized as a leading Canadian centre for research into amyotrophic lateral sclerosis (ALS) as well as for its care of ALS patients.
CQDM and Brain Canada join forces again in the funding of two new research projects to address unmet needs in brain research
CQDM and Brain Canada are proud to announce the funding of two new multi-disciplinary and multi-institutional research projects under the second edition of their Focus on Brain strategic initiative. The partners will award a total of $3M to two research teams to develop cutting-edge tools, technologies and platforms designed to accelerate the discovery of new drugs for brain and nervous system disorders.
MNI scientists will study stem cells, genetic mutations to develop new treatments
Researchers at the Montreal Neurological Institute of McGill University who are playing key roles in uncovering the mechanisms underlying ALS will share in $3.9 million in research funding, part of $4.5 million announced on Nov. 23 by the ALS Society of Canada in partnership with Brain Canada.
The Neuro is recognized as a major Canadian center for ALS research and patient care. During June, designated ALS Month, The Neuro redoubles its efforts to inform the public and the media about amyotrophic lateral sclerosis (ALS), and urges all to help support ALS research.
The ALS Ice Bucket Challenge One Year Later
On November 19 2015, marking the anniversary of the announcement of the 2014 ALS Ice Bucket Challenge results and partnership between ALS Canada and Brain Canada, ALS Canada was at The Montreal Neurological Institute and Hospital – The Neuro, to announce the final recipients of their 2015 grant competition. Four researchers and clinicians at The Neuro were among those recipients for their groundbreaking work in the ALS research field.
As a major Canadian centre for amyotrophic lateral sclerosis (ALS) research and treatment, the Montreal Neurological Institute and Hospital - The Neuro, invites the public and the media to learn more about the disease and current research and treatments, to donate money for ALS research and to wear the national emblem of ALS in Canada, the blue cornflower, during ALS Awareness Month in June.
What is ALS?
Mechanism meant to maintain efficiency of brain network involved in neurodegenerative disease
What is ALS?
Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease, is a neurodegenerative disease in which progressive muscle weakness leads to paralysis. ALS is a result of the death of motor neurons (nerve cells) in the brain and spinal cord that control voluntary muscle movement. Most people survive less than five years following diagnosis, but a small percentage of patients live for ten years or even longer. So far, there is no cure. About 3,000 Canadian adults have ALS and less than 1 in 10 patients have a family history of the disease.